Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs

Enquire | Email | Print

ISBN: GBIHC193MR
Published Date: May, 2012
Format: PDF
No of Pages: 63
 
 
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

Summary

The leading business intelligence provider, has released its latest research, “Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs”. It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Brazil with key data, information and analysis of the pricing and reimbursement steps in the country. The report closely scrutinizes the major changes in pharmaceuticals-related pricing and reimbursement in Brazil.

Due to the rapid growth in its economy, Brazil is increasingly becoming an affluent country, one which consistently spends a high proportion of its Gross domestic product (GDP) on healthcare (close to 9%, compared to the 10-12% of the US and 4-5% for other emerging nations). Through a comprehensive public health insurance programme, it aims to offer high quality healthcare provisions to the general population. While the pharmaceutical industry has grown due to the favorable regulations implemented by the government over the past two decades, the further growth of the market in Brazil will mainly arise through a direct correlation with GDP growth. This is in contrast to the growth due to an increase in the volume of the healthcare infrastructure witnessed in other emerging economies such as China and India.

The pricing of drugs in Brazil is mainly controlled by the government through various agencies such as the Agência Nacional de Vigilância Sanitária ANVISA which grants the marketing approval and the Câmara de Regulação do Mercado de Medicamentos CMED which is responsible for determining the price of new drugs and any subsequent annual price changes. While 70% of the population is covered under the public health insurance system implemented by the government, this amounts to only about 30% of the total government expenditure on drugs. About 58% of the total healthcare expenditure is accounted for by the private healthcare system. Special programs have been launched by the government to include the essential drug list, chronic diseases and diseases that require specialized treatments. Healthcare reimbursement has been well appreciated in Brazil, and many international health organizations, such as the World Health Organization (WHO) and the International Red Cross have lauded the efforts of the Brazilian government to reach out to the masses and make available quality healthcare at costs affordable to them.

Scope

- Detailed study of the healthcare scenario in Brazil.
- Analysis of the pricing and reimbursement mechanisms in Brazil.
- Details about government bodies which regulate different processes of pricing and reimbursement in Brazil.
- Details about the shares of major companies in the reimbursement program of Brazil.
- Insight into the various reimbursement programs available in Brazil.

Reasons to buy

- Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in Brazil.
- Optimize your investment through identification and understanding of the changes in the pharmaceutical regulatory mechanism in Brazil.
- Knowledge about the regulatory bodies who undertake different processes of price registration.
- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in pricing and reimbursement scene in Brazil.
- Negotiate better with the government agencies to maximize reimbursement on the drugs by understanding the mechanism.



1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9
2 Pricing and Reimbursement in Brazil - Introduction 10
3 Pricing and Reimbursement in Brazil - Overview 11
3.1 Trends in Population and Life Expectancy 11
3.1.1 Population of Brazil 11
3.1.2 Comparison of Population amongst BRIC Nations and the US 12
3.1.3 Life Expectancy 13
3.2 Socio-Economic and Demographic Trends 14
3.2.1 Shift in Demographics 14
3.2.2 Rise in Personal Disposable Income 16
3.2.3 Disease Burden 18
3.3 Healthcare in Brazil 20
3.3.1 Healthcare Expenditure in Brazil 20
3.3.2 Comparative Analysis 25
3.4 Healthcare System in Brazil 31
3.4.1 Health Workforce and Infrastructure in Brazil 31
4 Pricing and Reimbursement in Brazil - Introduction to Pharmaceutical Market of Brazil 37
4.1 Market Size and Market Forecasts 37
4.1.1 Pharmaceutical Market Sub-sectors 38
4.1.2 Pharmaceutical Market Share by Therapy Area 39
4.1.3 Opportunities and Challenges 40
5 Pricing and Reimbursement in Brazil - Healthcare Regulation 42
5.1 Introduction 42
5.2 Current Regulatory Framework 42
5.2.1 Agência Nacional de Vigilância Sanitária (ANVISA) 42
5.2.2 Drug Approval Process 44
5.2.3 Drug Registration Process 45
5.3 Patents and Generics (IPR) 46
5.4 Health Insurance Coverage 47
5.4.1 Public Insurance 47
5.4.2 Private Insurance 47
6 Pricing and Reimbursement in Brazil - Pricing 50
6.1 Pricing Policies 50
6.1.1 Annual Price Adjustments 51
6.2 Price - Setting Authorities 51
6.2.1 Ministry of Health (MOH) 51
6.2.2 Agência Nacional de Vigilância Sanitária (ANVISA) 52
6.2.3 National Agency for Supplementary Health (ANS) 52
7 Pricing and Reimbursement in Brazil - Reimbursement 53
7.1 The Reimbursement Process 53
7.1.1 SUS Sistema Único de Saúde (Unified Health System) 56
7.2 Health Technology Assessment (HTA) in Brazil’s Public Health System 57
7.2.1 Objectives of HTA 58
7.2.2 Department of Science and Technology (Departamento de Ciencia e Technologia - DECIT) 59
7.2.3 National Policy on Health Technology Management 59
8 Appendix 60
8.1 Market Definitions 60
8.2 Abbreviations 60
8.3 Sources 61
8.4 Research Methodology 61
8.4.1 Healthcare System 62
8.4.2 Pharmaceutical Regulations 62
8.4.3 Pricing of Pharmaceutical Drugs 62
8.4.4 Reimbursement of Pharmaceutical Drugs 62
8.4.5 Pricing and Reimbursement in Major Therapy Areas 63
8.5 Contact Us 63
8.6 Disclaimer 63

1.1 List of Tables
Table 1: Pricing and Reimbursement in Brazil, Population (million), 2005-2010 11
Table 2: Pricing and Reimbursement in Brazil, Population Estimates (million), 2010-2016 11
Table 3: Pricing and Reimbursement in Brazil, BRIC Nations and The US, Comparison of Population (million), 2005-2010 12
Table 4: Pricing and Reimbursement in Brazil, BRIC Nations and The US, Comparison of Population (million), 2010-2016 12
Table 5: Pricing and Reimbursement in Brazil, Average Life Expectancy (Years), 1960-2010 13
Table 6: Pricing and Reimbursement in Brazil, Population Age Structure (%), 1980-2050 14
Table 7: Pricing and Reimbursement in Brazil, Personal Disposable Income, Brazil ($bn), 2006-2010 16
Table 8: Pricing and Reimbursement in Brazil, Personal Disposable Income, Brazil ($bn), 2010-2015 16
Table 9: Pricing and Reimbursement in Brazil, Per Capita Personal Disposable Income, Brazil ($), 2006-2010 17
Table 10: Pricing and Reimbursement in Brazil, Per Capita Personal Disposable Income, Brazil ($), 2010-2015 17
Table 11: Pricing and Reimbursement in Brazil, All Causes of Death in Brazil, 2008 18
Table 12: Pricing and Reimbursement in Brazil, Total Healthcare Expenditure, % of GDP, 1995-2010 20
Table 13: Pricing and Reimbursement in Brazil, Public Healthcare Expenditure as Compared to Total Healthcare Expenditure, % of GDP, 1995-2010 21
Table 14: Pricing and Reimbursement in Brazil, Private and Public Healthcare Expenditure, % of Total Healthcare Expenditure, 1995-2002 22
Table 15: Pricing and Reimbursement in Brazil, Private and Public Health Expenditure, % of Total Health Expenditure, 2002-2010 22
Table 16: Pricing and Reimbursement in Brazil, Out-of-Pocket Healthcare Expenditure as % of Private Healthcare Expenditure, 1995-2002 23
Table 17: Pricing and Reimbursement in Brazil, Out-of-Pocket Healthcare Expenditure as % of Private Healthcare Expenditure, 2002-2009 24
Table 18: Pricing and Reimbursement in Brazil, Total Healthcare Expenditure as % of GDP, BRIC and The US, 2006-2009 25
Table 19: Pricing and Reimbursement in Brazil, Public Healthcare Spending as % of GDP, BRIC and The US, 2010-2050 26
Table 20: Pricing and Reimbursement in Brazil, Public Health Expenditure as % of Total Health Expenditure, BRIC and The US, 2006-2009 27
Table 21: Pricing and Reimbursement in Brazil, Per Capita Total Health Expenditure (PPP int. $), BRIC Countries, 2006-2009 28
Table 22: Pricing and Reimbursement in Brazil, Per Capita Public Health Expenditure (PPP int. $), BRIC Countries, 2006-2009 29
Table 23: Pricing and Reimbursement in Brazil, Out-of-Pocket Healthcare Expenditure as % of Private Healthcare Expenditure, BRIC and The US, 2006-2009 30
Table 24: Pricing and Reimbursement in Brazil, Number of Physicians, BRIC and The US, 2010 32
Table 25: Pricing and Reimbursement in Brazil, Number of Nursery and Midwifery Personnel, BRIC and The US, 2010 33
Table 26: Pricing and Reimbursement in Brazil, Number of Dentistry Personnel, BRIC and The US, 2010 34
Table 27: Pricing and Reimbursement in Brazil, Number of Pharmaceutical Personnel, BRIC and The US, 2010 35
Table 28: Pricing and Reimbursement in Brazil, Number of Hospital Beds per 10,000 Population, BRIC and The US, 2009 36
Table 29: Pricing and Reimbursement in Brazil, Pharmaceutical Market ($bn), 2004-2010 37
Table 30: Pricing and Reimbursement in Brazil, Pharmaceutical Market Forecasts ($bn), 2010-2018 37
Table 31: Pricing and Reimbursement in Brazil, Documents Required for Product Registration by ANVISA 46
Table 32: Pricing and Reimbursement in Brazil, Private Healthcare Coverage Providers, Number of Plan Members and Revenue ($m), 2010 49
Table 33: Pricing and Reimbursement in Brazil, Price Adjustments for Retail Drugs (%), 2004-2011 51
Table 34: Pricing and Reimbursement in Brazil, Institutional and Decision-making Structure of the SUS 56

1.2 List of Figures
Figure 1: Pricing and Reimbursement in Brazil, Population Estimates (million), 2005-2016 11
Figure 2: Pricing and Reimbursement in Brazil, BRIC Nations and The US, Comparison of Population (million), 2005-2016 12
Figure 3: Pricing and Reimbursement in Brazil, Average Life Expectancy (Years), 1960-2010 13
Figure 4: Pricing and Reimbursement in Brazil, Population Age Structure (%), 1980-2050 14
Figure 5: Pricing and Reimbursement in Brazil, Aging Index, 1980-2050 15
Figure 6: Pricing and Reimbursement in Brazil, Personal Disposable Income, Brazil ($bn), 2006-2015 16
Figure 7: Pricing and Reimbursement in Brazil, Per Capita Personal Disposable Income, Brazil ($), 2006-2015 17
Figure 8: Pricing and Reimbursement in Brazil, Top 10 Causes of Death in Brazil, 2008 18
Figure 9: Pricing and Reimbursement in Brazil, Total Healthcare Expenditure, % of GDP, 1995-2010 20
Figure 10: Pricing and Reimbursement in Brazil, Public Healthcare Expenditure Compared to Total Healthcare Expenditure, % of GDP, 1995-2010 21
Figure 11: Pricing and Reimbursement in Brazil, Private and Public Health Expenditure, % of Total Health Expenditure, 1995-2010 22
Figure 12: Pricing and Reimbursement in Brazil, Out-of-Pocket Healthcare Expenditure as % of Private Healthcare Expenditure, 1995-2009 23
Figure 13: Pricing and Reimbursement in Brazil, Total Healthcare Expenditure as % of GDP, BRIC and The US, 2006-2009 25
Figure 14: Pricing and Reimbursement in Brazil, Public Healthcare Spending as % of GDP, BRIC and The US, 2010-2050 26
Figure 15: Pricing and Reimbursement in Brazil, Public Healthcare Spending as % of GDP, BRIC and The US, 2006-2009 27
Figure 16: Pricing and Reimbursement in Brazil, Per Capita Total Health Expenditure (PPP int. $), BRIC Countries, 2006-2009 28
Figure 17: Pricing and Reimbursement in Brazil, Per Capita Public Health Expenditure (PPP Int. $), BRIC Countries, 2006-2009 29
Figure 18: Pricing and Reimbursement in Brazil, Out-of-Pocket Health Expenditure as % of Private Healthcare Expenditure, BRIC and The US, 2006-2009 30
Figure 19: Pricing and Reimbursement in Brazil, Number of Physicians per 10,000 Population, BRIC and The US, 2010 31
Figure 20: Pricing and Reimbursement in Brazil, Number of Nursery and Midwifery Personnel per 10,000 Population, BRIC and The US, 2010 33
Figure 21: Pricing and Reimbursement in Brazil, Number of Dentistry Personnel per 10,000 Population, BRIC and The US, 2010 34
Figure 22: Pricing and Reimbursement in Brazil, Number of Pharmacist per 10,000 Population, BRIC and The US, 2010 35
Figure 23: Pricing and Reimbursement in Brazil, Number of Hospital Beds per 10,000 Population, BRIC and The US, 2009 36
Figure 24: Pricing and Reimbursement in Brazil, Pharmaceutical Market Forecasts ($bn), 2004-2018 37
Figure 25: Pricing and Reimbursement in Brazil, Pharmaceutical Market by Sub-sectors (%), 2010 38
Figure 26: Pricing and Reimbursement in Brazil, Pharmaceutical Market by Sub-sectors (%), 2010 38
Figure 27: Pricing and Reimbursement in Brazil, Pharmaceutical Market by Sub-sectors (%), 2010 39
Figure 28: Pricing and Reimbursement in Brazil, Market Drivers and Opportunities 40
Figure 29: Pricing and Reimbursement in Brazil, Market Challenges 41
Figure 30: Pricing and Reimbursement in Brazil, Three Kinds of Drugs According to ANVISA 43
Figure 31: Pricing and Reimbursement in Brazil, Regulatory Approval Process for Clinical Trials 44
Figure 32: Pricing and Reimbursement in Brazil, Regulatory Approval Process for Clinical Trials 45
Figure 33: Pricing and Reimbursement in Brazil, Healthcare Coverage Provider, By Plan Members (%), 2009 48
Figure 34: Pricing and Reimbursement in Brazil, Price-setting Mechanism for New Molecules 50
Figure 35: Pricing and Reimbursement in Brazil, The Reimbursement Process 53
Figure 36: Pricing and Reimbursement in Brazil, Incorporation of Technologies Prior to Formation of CITEC, 2011 54
Figure 37: Pricing and Reimbursement in Brazil, Incorporation of Technologies After Formation of CITEC, 2011 55
Figure 38: Pricing and Reimbursement in Brazil, HTA within the Brazilian Ministry of Health, 2011 58



Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 246774, price: INR 213163, GBI Research

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online